Kenvue (KVUE Quick QuoteKVUE - Free Report) reported $3.84 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 4%. EPS of $0.29 for the same period compares to $0.32 a year ago.

The reported revenue represents a surprise of -0.51% over the Zacks Consensus Estimate of $3.86 billion. With the consensus EPS estimate being $0.28, the EPS surprise was +3.57%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Kenvue performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Self Care: $1.56 billion versus the two-analyst average estimate of $1.6 billion. The reported number represents a year-over-year change of -4.9%.
• Net Sales- Essential Health: $1.23 billion versus $1.23 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.
• Net Sales- Skin Health and Beauty: $1.06 billion versus the two-analyst average estimate of $1.04 billion. The reported number represents a year-over-year change of -4%.

View all Key Company Metrics for Kenvue here>>>

Shares of Kenvue have returned +3.3% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.